APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumonia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumonia Therapeutics Market Outlook and Growth Opportunities 2026

20 December 2025197 pages

Choose your research edition.

Industry ResearchPneumonia Therapeutics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumonia Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Pneumonia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumonia Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumonia Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Pneumonia Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumonia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumonia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumonia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumonia Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumonia Therapeutics market include Novartis, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Tetraphase Pharmaceuticals, Merck Sharp & Dohme and Biotest, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pneumonia Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumonia Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumonia Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pneumonia Therapeutics market.

Pneumonia Therapeutics Segment by Company

Novartis

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Tetraphase Pharmaceuticals

Merck Sharp & Dohme

Biotest

Pneumonia Therapeutics Segment by Type

Vaccines

Anti-Infectives

Oxygen Therapy

Pneumonia Therapeutics Segment by Application

Clinic

Hospital

Medical Center

Other

Pneumonia Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pneumonia Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pneumonia Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Pneumonia Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pneumonia Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumonia Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumonia Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumonia Therapeutics industry.

Chapter 3: Detailed analysis of Pneumonia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pneumonia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pneumonia Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumonia Therapeutics Industry Trends Table 2. Pneumonia Therapeutics Industry Drivers Table 3. Pneumonia Therapeutics Industry Opportunities and Challenges Table 4. Pneumonia Therapeutics Industry Restraints Table 5. Global Pneumonia Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumonia Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Pneumonia Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pneumonia Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Pneumonia Therapeutics Company, Product Type & Application Table 10. Global Pneumonia Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pneumonia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vaccines Table 15. Significant Companies of Anti-Infectives Table 16. Significant Companies of Oxygen Therapy Table 17. Global Pneumonia Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Pneumonia Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Pneumonia Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Pneumonia Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Pneumonia Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Clinic Table 23. Significant Companies of Hospital Table 24. Significant Companies of Medical Center Table 25. Significant Companies of Other Table 26. Global Pneumonia Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pneumonia Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Pneumonia Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Pneumonia Therapeutics Sales Value Share by Application (2021-2026) Table 30. Global Pneumonia Therapeutics Sales Value Share by Application (2027-2032) Table 31. Global Pneumonia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Pneumonia Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Pneumonia Therapeutics Sales Value Share by Region (2021-2026) Table 34. Global Pneumonia Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Pneumonia Therapeutics Sales Value Share by Region (2027-2032) Table 36. Global Pneumonia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pneumonia Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Pneumonia Therapeutics Sales Value Market Share by Country (2021-2026) Table 39. Global Pneumonia Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Pneumonia Therapeutics Sales Value Market Share by Country (2027-2032) Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Novartis Pneumonia Therapeutics Product Portfolio Table 45. Novartis Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Pfizer Pneumonia Therapeutics Product Portfolio Table 50. Pfizer Recent Development Table 51. GlaxoSmithKline Company Information Table 52. GlaxoSmithKline Business Overview Table 53. GlaxoSmithKline Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. GlaxoSmithKline Pneumonia Therapeutics Product Portfolio Table 55. GlaxoSmithKline Recent Development Table 56. Bayer Company Information Table 57. Bayer Business Overview Table 58. Bayer Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Bayer Pneumonia Therapeutics Product Portfolio Table 60. Bayer Recent Development Table 61. AstraZeneca Company Information Table 62. AstraZeneca Business Overview Table 63. AstraZeneca Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. AstraZeneca Pneumonia Therapeutics Product Portfolio Table 65. AstraZeneca Recent Development Table 66. Tetraphase Pharmaceuticals Company Information Table 67. Tetraphase Pharmaceuticals Business Overview Table 68. Tetraphase Pharmaceuticals Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Tetraphase Pharmaceuticals Pneumonia Therapeutics Product Portfolio Table 70. Tetraphase Pharmaceuticals Recent Development Table 71. Merck Sharp & Dohme Company Information Table 72. Merck Sharp & Dohme Business Overview Table 73. Merck Sharp & Dohme Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck Sharp & Dohme Pneumonia Therapeutics Product Portfolio Table 75. Merck Sharp & Dohme Recent Development Table 76. Biotest Company Information Table 77. Biotest Business Overview Table 78. Biotest Pneumonia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biotest Pneumonia Therapeutics Product Portfolio Table 80. Biotest Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Pneumonia Therapeutics Product Image Figure 2. Global Pneumonia Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumonia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumonia Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vaccines Image Figure 8. Anti-Infectives Image Figure 9. Oxygen Therapy Image Figure 10. Global Pneumonia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Pneumonia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Pneumonia Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Medical Center Image Figure 16. Other Image Figure 17. Global Pneumonia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pneumonia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pneumonia Therapeutics Sales Value Share by Application (2021-2032) Figure 20. Global Pneumonia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Pneumonia Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Pneumonia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Pneumonia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Pneumonia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Pneumonia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Pneumonia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Pneumonia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Pneumonia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Pneumonia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Pneumonia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Pneumonia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Pneumonia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Anti-Infectives
  • Oxygen Therapy
Applications
  • Clinic
  • Hospital
  • Medical Center
  • Other
Companies covered
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Tetraphase Pharmaceuticals
  • Merck Sharp & Dohme
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pneumonia Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pneumonia Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pneumonia Therapeutics Market Dynamics
  1. 2.1 Pneumonia Therapeutics Industry Trends
  2. 2.2 Pneumonia Therapeutics Industry Drivers
  3. 2.3 Pneumonia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Pneumonia Therapeutics Industry Restraints
3 Pneumonia Therapeutics Market by Company
  1. 3.1 Global Pneumonia Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Pneumonia Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Pneumonia Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Pneumonia Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Pneumonia Therapeutics Company Product Type and Application
  6. 3.6 Global Pneumonia Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pneumonia Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pneumonia Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pneumonia Therapeutics Market by Type
  1. 4.1 Pneumonia Therapeutics Type Introduction
  2. 4.1.1 Vaccines
  3. 4.1.2 Anti-Infectives
  4. 4.1.3 Oxygen Therapy
  5. 4.2 Global Pneumonia Therapeutics Sales Value by Type
  6. 4.2.1 Global Pneumonia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pneumonia Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Pneumonia Therapeutics Sales Value Share by Type (2021-2032)
5 Pneumonia Therapeutics Market by Application
  1. 5.1 Pneumonia Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Medical Center
  5. 5.1.4 Other
  6. 5.2 Global Pneumonia Therapeutics Sales Value by Application
  7. 5.2.1 Global Pneumonia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Pneumonia Therapeutics Sales Value by Application (2021-2032)
  9. 5.2.3 Global Pneumonia Therapeutics Sales Value Share by Application (2021-2032)
6 Pneumonia Therapeutics Regional Value Analysis
  1. 6.1 Global Pneumonia Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumonia Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pneumonia Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pneumonia Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pneumonia Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Pneumonia Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pneumonia Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Pneumonia Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pneumonia Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pneumonia Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pneumonia Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Pneumonia Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pneumonia Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pneumonia Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Pneumonia Therapeutics Country-level Value Analysis
  1. 7.1 Global Pneumonia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumonia Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pneumonia Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pneumonia Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pneumonia Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pneumonia Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pneumonia Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Pneumonia Therapeutics Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Pneumonia Therapeutics Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Pneumonia Therapeutics Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Pneumonia Therapeutics Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Pneumonia Therapeutics Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Tetraphase Pharmaceuticals
  32. 8.6.1 Tetraphase Pharmaceuticals Company Information
  33. 8.6.2 Tetraphase Pharmaceuticals Business Overview
  34. 8.6.3 Tetraphase Pharmaceuticals Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Tetraphase Pharmaceuticals Pneumonia Therapeutics Product Portfolio
  36. 8.6.5 Tetraphase Pharmaceuticals Recent Developments
  37. 8.7 Merck Sharp & Dohme
  38. 8.7.1 Merck Sharp & Dohme Company Information
  39. 8.7.2 Merck Sharp & Dohme Business Overview
  40. 8.7.3 Merck Sharp & Dohme Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Sharp & Dohme Pneumonia Therapeutics Product Portfolio
  42. 8.7.5 Merck Sharp & Dohme Recent Developments
  43. 8.8 Biotest
  44. 8.8.1 Biotest Company Information
  45. 8.8.2 Biotest Business Overview
  46. 8.8.3 Biotest Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biotest Pneumonia Therapeutics Product Portfolio
  48. 8.8.5 Biotest Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst